New advances in the diagnosis and treatment of biliary atresia.
10.7499/j.issn.1008-8830.2205180
- Author:
Yan-Fu WANG
1
;
Jian-Hua FU
;
Zhi-Bo ZHANG
1
Author Information
1. Department of Neonatal Surgery/Pediatric Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.
- Publication Type:Journal Article
- Keywords:
Biliary atresia;
Biomarker;
Diagnosis;
Neonate;
Treatment
- MeSH:
Humans;
Biliary Atresia/therapy*;
Portoenterostomy, Hepatic/methods*;
Liver Transplantation/methods*;
Prognosis;
Biomarkers
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(11):1269-1274
- CountryChina
- Language:Chinese
-
Abstract:
The diagnosis of biliary atresia (BA) is mainly based on clinical manifestations, screening, and related biochemistry tests. In recent years, the development of blood biomarkers and the improvement in ultrasound examination have made it possible for BA to be diagnosed at a younger age. In particular, matrix metalloproteinase-7 shows high sensitivity and specificity and has a higher diagnostic efficiency than existing biochemical parameters, thereby holding a promise for clinical application. Sound touch elastography can increase the diagnostic efficiency for BA in terms of diagnosis and prognostic evaluation. Surgery is still the only method for the treatment of BA at present, with the preferred surgical treatment regimen of Kasai portoenterostomy combined with pharmacotherapies for alleviating infection and inflammation, and the patients who fail Kasai portoenterostomy or have liver dysfunction may require liver transplantation to save their lives. Therefore, the current research on BA should focus on the biomarkers for early diagnosis, specifically targeted drugs, and drugs for preventing progressive liver fibrosis. This article reviews the current diagnosis and treatment methods for BA and discusses the potential research directions.
